Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation

被引:54
作者
Dudziak, D
Nimmerjahn, F
Bornkamm, GW
Laux, G
机构
[1] Tech Univ Munich, GSF & Childrens Hosp, Inst Clin Mol Biol & Tumor Genet, GSF Natl Res Ctr Environm & Hlth, D-8000 Munich, Germany
[2] Tech Univ Munich, GSF & Childrens Hosp, Clin Cooperat Grp Pediat Oncol, D-8000 Munich, Germany
关键词
D O I
10.4049/jimmunol.174.11.6672
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD83 is expressed on mature dendritic cells and activated lymphocytes and has been implicated to play an important role during T cell development in the thymus. In contrast, not much is known about the function of CD83 in the periphery. Soluble forms of CD83 have been detected in the serum, but neither the function nor the mechanism of how these soluble forms of CD83 are generated are fully understood. In this study, we report the identification of four different transcripts of CD83 in unstimulated PBMCs. Sequence analysis demonstrated that the longest form codes for transmembrane CD83 (CD83-TM), whereas the smaller transcripts are splice variants of full-length CD83, coding for putative soluble CD83 proteins. Stimulation of PBMCs with PHA, TNF-alpha, or LPS leads to the up-regulation of the full-length CD83 transcript and to a strong down-regulation of two of the three smaller transcripts. The smallest CD83 splice product can be translated efficiently into protein, and recombinant soluble CD83 shows a strong inhibitory effect on T cell proliferation in MLRs. Our results suggest that the constitutive production of soluble forms of CD83 under steady-state conditions may have an important function in regulating immune homeostasis.
引用
收藏
页码:6672 / 6676
页数:5
相关论文
共 39 条
[1]   The PI3 kinase, p38 SAP kinase, and NF-κB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells [J].
Ardeshna, KM ;
Pizzey, AR ;
Devereaux, S ;
Khwaja, A .
BLOOD, 2000, 96 (03) :1039-1046
[2]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[3]   ACTIVATION OF HUMAN DENDRITIC CELLS THROUGH CD40 CROSS-LINKING [J].
CAUX, C ;
MASSACRIER, C ;
VANBERVLIET, B ;
DUBOIS, B ;
VANKOOTEN, C ;
DURAND, I ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1263-1272
[4]   PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE [J].
CHENG, JH ;
ZHOU, T ;
LIU, CD ;
SHAPIRO, JP ;
BRAUER, MJ ;
KIEFER, MC ;
BARR, PJ ;
MOUNTZ, JD .
SCIENCE, 1994, 263 (5154) :1759-1762
[5]   Activation-induced expression of murine CD83 on T cells and identification of a specific CD83 ligand on murine B cells [J].
Cramer, SO ;
Trumpfheller, C ;
Mehlhoop, U ;
Moré, S ;
Fleischer, B ;
von Bonin, A .
INTERNATIONAL IMMUNOLOGY, 2000, 12 (09) :1347-1351
[6]   Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-κB signaling pathway [J].
Dudziak, D ;
Kieser, A ;
Dirmeier, U ;
Nimmerjahn, F ;
Berchtold, S ;
Steinkasserer, A ;
Marschall, G ;
Hammerschmidt, W ;
Laux, G ;
Bornkamm, GW .
JOURNAL OF VIROLOGY, 2003, 77 (15) :8290-8298
[7]   NEW CD FROM THE B-CELL SECTION OF THE 5TH-INTERNATIONAL-WORKSHOP-ON-HUMAN-LEUKOCYTE-DIFFERENTIATION-ANTIGENS [J].
ENGEL, P ;
TEDDER, TF .
LEUKEMIA & LYMPHOMA, 1994, 13 :61-64
[8]   CD83 expression influences CD4+ T cell development in the thymus [J].
Fujimoto, Y ;
Tu, LL ;
Miller, AS ;
Bock, C ;
Fujimoto, M ;
Doyle, C ;
Steeber, DA ;
Tedder, TF .
CELL, 2002, 108 (06) :755-767
[9]   CLONING OF THE HUMAN AND MURINE INTERLEUKIN-7 RECEPTORS - DEMONSTRATION OF A SOLUBLE FORM AND HOMOLOGY TO A NEW RECEPTOR SUPERFAMILY [J].
GOODWIN, RG ;
FRIEND, D ;
ZIEGLER, SF ;
JERZY, R ;
FALK, BA ;
GIMPEL, S ;
COSMAN, D ;
DOWER, SK ;
MARCH, CJ ;
NAMEN, AE ;
PARK, LS .
CELL, 1990, 60 (06) :941-951
[10]   The soluble form of CD83 is present at elevated levels in a number of hematological malignancies [J].
Hock, BD ;
Haring, LF ;
Steinkasserer, A ;
Taylor, KG ;
Patton, WN ;
McKenzie, JL .
LEUKEMIA RESEARCH, 2004, 28 (03) :237-241